Lenalidomide Zentiva

Lenalidomide, the active ingredient in Lenalidomide Zentiva, is a Immunomodulatory agent presented as a tablet for oral use. It is used to treat certain blood cancers, primarily in adult patients. GNH USA supplies Lenalidomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is an immunomodulatory antineoplastic that targets malignant plasma cells and dysplastic bone‑marrow clones. - Multiple myeloma: helps control disease progression and improve survival in patients who have received prior therapy. - Myelodysplastic syndromes: reduces transfusion dependence and may modify disease course in patients with del(5q) cytogenetic abnormality.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Thrombocytopenia: lowered platelet count causing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Constipation: difficulty passing stools. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression requiring medical intervention. - Hepatotoxicity: liver enzyme elevations indicating possible liver injury. - Secondary malignancies: emergence of new cancers during treatment. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythms in susceptible patients.

Patients receiving Lenalidomide should be monitored closely for safety concerns. - Blood monitoring: regular complete blood counts to detect cytopenias. - Thrombotic risk assessment: evaluate need for prophylactic anticoagulation. - Pregnancy avoidance: enforce strict contraception due to teratogenic potential. - Renal function: adjust therapy in patients with impaired kidney function. - Drug interaction review: assess concomitant medications for potential interactions. - Store at room temperature: keep in original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of thromboembolic events. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug effectiveness. - NSAIDs: potential additive effect on platelet inhibition. - Antihypertensives: monitor blood pressure as lenalidomide can cause fluid shifts.